While the mechanism of action of mesalamine is not well understood, it remains clinically effective in mild to moderate ulcerative colitis, possibly because it can modulate several inflammatory pathways (including those associated with PPARγ, arachidonic acid and leukotriene biosynthesis, NFκB, and mTOR). This evidence concerns the gene MTOR and ulcerative colitis.